MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
9.86
+0.08
+0.82%
After Hours: 9.86 0 0.00% 16:10 11/13 EST
OPEN
9.76
PREV CLOSE
9.78
HIGH
10.15
LOW
9.36
VOLUME
265.89K
TURNOVER
--
52 WEEK HIGH
17.79
52 WEEK LOW
6.73
MARKET CAP
387.16M
P/E (TTM)
-5.5731
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTNM last week (1102-1106)?
Weekly Report · 6d ago
Based on the search results, I can see that Contineum Therapeutics just reported Q3 2026 earnings on Tuesday (November 3, 2026), missing estimates, and the company's partnered asset PIPE-307 failed its Phase 2 trial in September 2026. The company is now deferring the CTX-343 program to prioritize resources for PIPE-791, and maintains a cash runway through mid-2029.
Barchart · 11/04 16:15
Contineum’s PROPEL-IPF Progress and Upcoming Catalysts Support Buy Rating; $30 Price Target Unchanged
TipRanks · 11/04 00:15
Contineum Therapeutics GAAP EPS of -$0.49
Seeking Alpha · 11/03 22:31
Press Release: Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Dow Jones · 11/03 21:05
Weekly Report: what happened at CTNM last week (1026-1030)?
Weekly Report · 11/02 10:23
We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth
Simply Wall St · 10/30 11:33
Contineum's IPF Bet Takes Center Stage Tomorrow, But Bristol's Data Still Looms
Barchart · 10/28 16:06
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.